Cargando…

2248. Changes in Lipid Profiles for Patients to Tenofovir Alafenamide (TAF)-Containing Regimens: Perspectives from a Military HIV-Positive Cohort

BACKGROUND: Tenofovir alafenamide (TAF) was approved in 2015 for use in HIV-1. TAF decreases risk of renal and bone toxicity compared with tenofovir disproxil fumarate (TDF). Early clinical trials reported median increases in low-density lipoprotein (LDL) of 20–29 and 9–13 mg/dL for total cholestero...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ewers, Evan, Won, Seunghyun, Okulicz, Jason, Ferguson, Tomas, Deiss, Robert, Maves, Ryan, Kronmann, Karl, Lalani, Tahaniyat, Agan, Brian, Whitman, Timothy J, Ganesan, Anuradha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252728/ http://dx.doi.org/10.1093/ofid/ofy210.1901

Ejemplares similares

1014. Factors Associated with Switching from Tenofovir Diproxil Phosphate to a Tenofovir Alafenamide Based Regimen in a Cohort with Unrestricted Access to Care and Medications
por: Ganesan, Anuradha, et al.
Publicado: (2020)

571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed
por: Ganesan, Anuradha, et al.
Publicado: (2018)

336. Disparities in Cardiovascular Disease Prevention Among Persons Living with HIV in the United States Military Natural History Study
por: Thomas Larson, Derek, et al.
Publicado: (2019)

1263. Anti-Retroviral (ART) Success in an Active Duty Military Cohort from 2002 to 2016, A Model for Ending the HIV Epidemic in the United States
por: Schofield, Christina, et al.
Publicado: (2019)

369. Association Between Depression and HIV Treatment Outcomes in a US Military Population with HIV Infection
por: Carney, Brandon, et al.
Publicado: (2019)

601. Prescription Drug Misuse in an HIV-Infected US Military Cohort
por: Deiss, Robert, et al.
Publicado: (2018)

Association between depression and HIV treatment outcomes in a US military population with HIV infection
por: Carney, Brandon, et al.
Publicado: (2021)

Gonorrhea (GC) and Chlamydia (CT) Infection in a Large, Well-Characterized Military Cohort: Prevalence, Incidence, Site of Infection, and Patient Characteristics
por: Eickhoff, Christa, et al.
Publicado: (2017)

The Impact of Continuous Virologic Suppression on the Development of Non-AIDS Diagnoses
por: Joya, Christie, et al.
Publicado: (2017)

1752 Incident Genitourinary and Extragenital Gonococcal and Chlamydial infections in a Racially Diverse Well Characterized Cohort of HIV-infected Persons with Free Access to Care and Counseling
por: Lee, Tida, et al.
Publicado: (2014)

Calculated Globulin Adds Predictive Value to Hepatitis B Vaccine Response in HIV-infected Persons Independently of HIV Viral load and CD4 Cell Count
por: O’Bryan, Thomas, et al.
Publicado: (2017)

185. Despite the Availability of Free Testing and Care Testing for Extragenital Sexually Transmitted Infections in a Cohort of Hiv-infected Department of Defense Beneficiaries Is Low and Similar to the Rates Observed Nationwide
por: Ganesan, Anuradha, et al.
Publicado: (2020)

Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)
por: Thimm, Matthew A., et al.
Publicado: (2022)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
por: Squillace, Nicola, et al.
Publicado: (2020)

Exosomal lncRNA HOTTIP Mediates Antiviral Effect of Tenofovir Alafenamide (TAF) on HBV Infection
por: Liu, Qing-Min, et al.
Publicado: (2021)

Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen
por: Darnell, Julia, et al.
Publicado: (2021)

Risk Factors Associated With Chronic Liver Enzyme Elevation in Persons With HIV Without Hepatitis B or C Coinfection in the Combination Antiretroviral Therapy Era
por: Wood, Shannon, et al.
Publicado: (2021)

Comparative Pharmacokinetics and Local Tolerance of Tenofovir Alafenamide (TAF) From Subcutaneous Implant in Rabbits, Dogs, and Macaques
por: Gatto, G. J., et al.
Publicado: (2022)

1566 Factors Associated with 10 Years of Continuous HIV Viral Load Suppression on HAART
por: Bello, Kathryn, et al.
Publicado: (2014)

Hospitalizations among HIV controllers and persons with medically controlled HIV in the U.S. Military HIV Natural History Study
por: Crowell, Trevor A, et al.
Publicado: (2016)

High-risk Behavior Among U.S. Military HIV-Infected Active-Duty and Retired Personnel
por: Pannebaker, Danielle, et al.
Publicado: (2017)

A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination
por: Sax, Paul E, et al.
Publicado: (2017)

Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting
por: Romano, Joseph W., et al.
Publicado: (2021)

Prescribing rates and characteristics of recipients of tenofovir-containing regimens before and after market entry of tenofovir alafenamide
por: Hung, Anna, et al.
Publicado: (2020)

LB-7. Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)
por: Sax, Paul, et al.
Publicado: (2020)

Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP)
por: Johnson, Leah M., et al.
Publicado: (2019)

335. Antiretroviral Therapy Anchor-based Trends in Body Mass Index following Treatment Initiation among Military Personnel with HIV
por: Kline, David, et al.
Publicado: (2019)

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018)

1561. Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Dolutegravir (DTG)-Based 3-Drug Regimens in Adults With HIV Who Have Suboptimal Antiretroviral Adherence
por: Andreatta, Kristen, et al.
Publicado: (2023)

The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
por: Wang, Huilian, et al.
Publicado: (2016)

A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
por: Gomez, Mario, et al.
Publicado: (2018)

Correction to: A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
por: Gomez, Mario, et al.
Publicado: (2018)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)

Factors associated with 10 years of continuous viral load suppression on HAART
por: Bello, Kathryn J., et al.
Publicado: (2016)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
por: Lalley-Chareczko, Linden, et al.
Publicado: (2020)

1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis
por: Eron, Joseph J, et al.
Publicado: (2020)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

1561 The Relationship Between Self-reported Adherence and Efavirenz Blood Levels on the Appearance of HIV Viral Load Blips
por: Farmer, Aaron, et al.
Publicado: (2014)

318. Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) in Hispanic/Latinx and Black Participants: Efficacy, Bone and Renal Safety Results from a Pooled Analysis of 7 Clinical Trials
por: DeJesus, Edwin, et al.
Publicado: (2019)

1072 Utilization of pre-travel clinic for administration of routine vaccinations in adults: a lost opportunity?
por: Clair, Kristina J. St., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7kjejvburctds539dl998n2lco